Skip to main content
IONS
NASDAQ Life Sciences

EU Regulators Grant TRYNGOLZA Broader Approval in Severe Hypertriglyceridemia

Tom Rudovsky · Reported by Wiseek News
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$28.02
Mkt Cap
$4.665B
52W Low
$27.25
52W High
$86.74
52W Position info
2.8% above low
Off High info
68% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

IONS is trading near its 52-week low of $27.25 (2.8% above the low).

Summary

The European Commission approved TRYNGOLZA (olezarsen) for adults with severe hypertriglyceridemia, widening the EU label beyond familial chylomicronemia syndrome. This converts the positive CHMP opinion from October 16 into a final authorization, so the regulatory step is done and the question shifts to launch and reimbursement. The approval rests on Phase 3 CORE and CORE2, which cut fasting triglycerides and acute pancreatitis events versus placebo, though the release gives no effect sizes. Commercial value to Ionis is indirect: Sobi holds exclusive ex-U.S. rights outside Canada and China, and the license terms were not disclosed. The timing matters because on November 9 Ionis cut 2026 TRYNGOLZA sales guidance to about $100 million alongside Q3 revenue of $243 million and a $0.66 per-share loss — the stock sits near its 52-week low, so a broader EU label is a modest positive against a damaged near-term sales story.

At the time of this announcement, IONS was trading at $28.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.7B. The 52-week trading range was $27.25 to $86.74. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.


Price Chart

Share this article

Copied!

IONS - Latest Insights

IONS
Nov 10, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $31.17
Real-time Price: $28.02 info
Change: -$3.15 (-10%) info
Market Cap: $4.665B info
IONS
Nov 09, 2026, 11:01 AM EST
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $28.67
Real-time Price: $28.02 info
Change: -$0.645 (-2%) info
Market Cap: $4.665B info
IONS
Nov 09, 2026, 8:33 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $31.50
Real-time Price: $28.02 info
Change: -$3.48 (-11%) info
Market Cap: $4.665B info
IONS
Nov 09, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $37.00
Real-time Price: $28.02 info
Change: -$8.98 (-24%) info
Market Cap: $4.665B info
IONS
Nov 09, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $37.00
Real-time Price: $28.02 info
Change: -$8.98 (-24%) info
Market Cap: $4.665B info